canakinumab
novartis
['improve ', 'canakinumab', 'canopy-a']
adjuvant canakinumab did not improve dfs (hr 0.939). canopy-a clearly a negative study. #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him